 Kristine Kuhn
Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spondylarthritis | 14 | 2025 | 45 | 6.150 |
Why?
| | Microbiota | 13 | 2025 | 729 | 3.870 |
Why?
| | Gastrointestinal Microbiome | 15 | 2025 | 640 | 3.450 |
Why?
| | Arthritis, Rheumatoid | 18 | 2025 | 1097 | 3.420 |
Why?
| | Spondylitis, Ankylosing | 6 | 2022 | 46 | 3.000 |
Why?
| | Arthritis, Experimental | 7 | 2025 | 135 | 2.150 |
Why?
| | Intraepithelial Lymphocytes | 3 | 2024 | 14 | 2.050 |
Why?
| | Intestinal Mucosa | 7 | 2024 | 589 | 1.900 |
Why?
| | Inflammatory Bowel Diseases | 10 | 2025 | 320 | 1.880 |
Why?
| | Intestines | 5 | 2021 | 347 | 1.690 |
Why?
| | Interleukin-17 | 3 | 2023 | 108 | 1.620 |
Why?
| | Crohn Disease | 4 | 2024 | 215 | 1.530 |
Why?
| | Arthritis | 4 | 2022 | 90 | 1.510 |
Why?
| | Colon | 4 | 2024 | 252 | 1.390 |
Why?
| | Autoimmune Diseases | 4 | 2024 | 426 | 1.160 |
Why?
| | Rheumatology | 3 | 2024 | 107 | 1.130 |
Why?
| | Inflammation | 10 | 2023 | 2737 | 1.050 |
Why?
| | Immunity, Mucosal | 5 | 2020 | 94 | 1.050 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2024 | 96 | 0.990 |
Why?
| | Arthritis, Juvenile | 1 | 2025 | 53 | 0.910 |
Why?
| | Sphingosine | 1 | 2024 | 40 | 0.880 |
Why?
| | Th17 Cells | 2 | 2024 | 83 | 0.880 |
Why?
| | Lysophospholipids | 1 | 2024 | 72 | 0.870 |
Why?
| | Dysbiosis | 4 | 2022 | 169 | 0.860 |
Why?
| | Tryptophan | 2 | 2023 | 178 | 0.840 |
Why?
| | Musculoskeletal Diseases | 1 | 2024 | 69 | 0.830 |
Why?
| | Autoantibodies | 6 | 2024 | 1467 | 0.830 |
Why?
| | Myeloid Cells | 1 | 2024 | 141 | 0.820 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2024 | 336 | 0.780 |
Why?
| | Interleukin-6 | 2 | 2017 | 720 | 0.770 |
Why?
| | T-Lymphocytes | 3 | 2021 | 1933 | 0.740 |
Why?
| | Immunoglobulin A | 1 | 2022 | 200 | 0.720 |
Why?
| | Biomedical Research | 2 | 2024 | 637 | 0.680 |
Why?
| | Mentoring | 1 | 2022 | 127 | 0.670 |
Why?
| | Metabolomics | 3 | 2025 | 652 | 0.660 |
Why?
| | Mice | 22 | 2025 | 16915 | 0.650 |
Why?
| | Metagenomics | 1 | 2021 | 155 | 0.650 |
Why?
| | Mice, Knockout | 2 | 2024 | 2871 | 0.640 |
Why?
| | Animals | 28 | 2025 | 35309 | 0.620 |
Why?
| | Osteoarthritis | 1 | 2020 | 168 | 0.570 |
Why?
| | Bacteroidaceae | 1 | 2017 | 3 | 0.570 |
Why?
| | Citrobacter rodentium | 1 | 2017 | 7 | 0.570 |
Why?
| | Enterobacteriaceae Infections | 1 | 2017 | 41 | 0.550 |
Why?
| | Humans | 51 | 2025 | 129271 | 0.520 |
Why?
| | Skin | 2 | 2020 | 726 | 0.490 |
Why?
| | Gastrointestinal Tract | 1 | 2018 | 185 | 0.490 |
Why?
| | Disease Models, Animal | 9 | 2025 | 4057 | 0.450 |
Why?
| | Collagen Type II | 2 | 2018 | 48 | 0.440 |
Why?
| | Collagen | 4 | 2023 | 433 | 0.430 |
Why?
| | Anti-Citrullinated Protein Antibodies | 3 | 2024 | 109 | 0.390 |
Why?
| | Bacteria | 3 | 2025 | 813 | 0.380 |
Why?
| | Antirheumatic Agents | 2 | 2024 | 280 | 0.360 |
Why?
| | Cytokines | 6 | 2022 | 2013 | 0.360 |
Why?
| | Antigens | 2 | 2013 | 356 | 0.350 |
Why?
| | Receptors, Complement 3d | 2 | 2008 | 141 | 0.340 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2025 | 522 | 0.320 |
Why?
| | Immunity, Innate | 3 | 2020 | 803 | 0.310 |
Why?
| | Germ-Free Life | 4 | 2025 | 33 | 0.300 |
Why?
| | Receptors, Complement 3b | 1 | 2008 | 84 | 0.290 |
Why?
| | Biomarkers | 4 | 2024 | 3968 | 0.280 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1367 | 0.280 |
Why?
| | HLA-B27 Antigen | 2 | 2024 | 15 | 0.280 |
Why?
| | Cell Proliferation | 1 | 2014 | 2375 | 0.270 |
Why?
| | Feces | 4 | 2025 | 441 | 0.260 |
Why?
| | Mice, Inbred C57BL | 7 | 2025 | 5439 | 0.260 |
Why?
| | Phytochemicals | 1 | 2025 | 13 | 0.230 |
Why?
| | Symbiosis | 2 | 2017 | 71 | 0.230 |
Why?
| | Tea | 1 | 2025 | 20 | 0.230 |
Why?
| | Arthritis, Psoriatic | 1 | 2024 | 20 | 0.230 |
Why?
| | Hypoxia-Inducible Factor 1 | 2 | 2015 | 72 | 0.230 |
Why?
| | Peptides, Cyclic | 1 | 2006 | 256 | 0.220 |
Why?
| | Fingolimod Hydrochloride | 1 | 2024 | 39 | 0.220 |
Why?
| | Ileitis | 1 | 2023 | 32 | 0.210 |
Why?
| | Congresses as Topic | 1 | 2024 | 216 | 0.210 |
Why?
| | Bifidobacterium longum | 1 | 2022 | 6 | 0.200 |
Why?
| | Autoantigens | 2 | 2022 | 419 | 0.200 |
Why?
| | Colitis | 2 | 2015 | 241 | 0.200 |
Why?
| | Erythema Nodosum | 1 | 2022 | 3 | 0.200 |
Why?
| | Mucous Membrane | 2 | 2024 | 122 | 0.200 |
Why?
| | Oryza | 1 | 2022 | 31 | 0.190 |
Why?
| | Pyoderma Gangrenosum | 1 | 2022 | 8 | 0.190 |
Why?
| | Disease Susceptibility | 2 | 2021 | 333 | 0.190 |
Why?
| | Case-Control Studies | 2 | 2021 | 3377 | 0.190 |
Why?
| | Granzymes | 1 | 2021 | 47 | 0.180 |
Why?
| | Uveitis | 1 | 2022 | 127 | 0.180 |
Why?
| | Mentors | 1 | 2022 | 178 | 0.180 |
Why?
| | Cell Differentiation | 2 | 2024 | 1887 | 0.170 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 178 | 0.170 |
Why?
| | United States | 4 | 2025 | 13828 | 0.170 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 179 | 0.160 |
Why?
| | Bacteriophages | 1 | 2021 | 86 | 0.160 |
Why?
| | Bacteroides | 2 | 2019 | 19 | 0.160 |
Why?
| | Glucose Intolerance | 1 | 2021 | 142 | 0.160 |
Why?
| | Fatty Acids, Volatile | 2 | 2018 | 57 | 0.150 |
Why?
| | Adaptive Immunity | 1 | 2020 | 161 | 0.150 |
Why?
| | Homeodomain Proteins | 1 | 2022 | 495 | 0.150 |
Why?
| | Disease | 1 | 2019 | 95 | 0.150 |
Why?
| | Epithelial Cells | 2 | 2015 | 1063 | 0.150 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 323 | 0.150 |
Why?
| | Immunoglobulin G | 1 | 2022 | 848 | 0.150 |
Why?
| | Mice, Transgenic | 2 | 2022 | 2117 | 0.150 |
Why?
| | Lymphocytes | 1 | 2020 | 378 | 0.150 |
Why?
| | Male | 17 | 2025 | 63517 | 0.150 |
Why?
| | Immune System | 1 | 2019 | 175 | 0.150 |
Why?
| | Vascular Diseases | 1 | 2021 | 240 | 0.150 |
Why?
| | Homosexuality, Male | 1 | 2019 | 176 | 0.140 |
Why?
| | HIV | 1 | 2019 | 227 | 0.140 |
Why?
| | Monocytes | 1 | 2020 | 551 | 0.140 |
Why?
| | Immune Tolerance | 1 | 2020 | 355 | 0.140 |
Why?
| | Risk Factors | 4 | 2025 | 9746 | 0.140 |
Why?
| | Cell Membrane Permeability | 1 | 2017 | 82 | 0.140 |
Why?
| | Pilot Projects | 1 | 2022 | 1584 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 543 | 0.130 |
Why?
| | Computational Biology | 1 | 2021 | 595 | 0.130 |
Why?
| | Obesity | 2 | 2021 | 2879 | 0.130 |
Why?
| | Female | 15 | 2025 | 68556 | 0.130 |
Why?
| | Antibody Formation | 2 | 2008 | 291 | 0.130 |
Why?
| | Sulfatases | 1 | 2015 | 2 | 0.120 |
Why?
| | Histones | 1 | 2020 | 588 | 0.120 |
Why?
| | Claudin-1 | 1 | 2015 | 21 | 0.120 |
Why?
| | Secretory Vesicles | 1 | 2015 | 24 | 0.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 260 | 0.120 |
Why?
| | Antigens, Bacterial | 1 | 2015 | 119 | 0.110 |
Why?
| | Tight Junctions | 1 | 2015 | 75 | 0.110 |
Why?
| | Molecular Mimicry | 1 | 2014 | 38 | 0.110 |
Why?
| | Software | 1 | 2019 | 606 | 0.110 |
Why?
| | Autoimmunity | 3 | 2020 | 862 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1482 | 0.110 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1688 | 0.110 |
Why?
| | Homeostasis | 1 | 2017 | 605 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1432 | 0.110 |
Why?
| | Genome-Wide Association Study | 1 | 2020 | 1327 | 0.110 |
Why?
| | Physicians | 1 | 2021 | 859 | 0.100 |
Why?
| | Rheumatologists | 2 | 2023 | 15 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1708 | 0.100 |
Why?
| | Wound Healing | 1 | 2014 | 306 | 0.100 |
Why?
| | Middle Aged | 10 | 2025 | 31091 | 0.100 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 351 | 0.090 |
Why?
| | Adult | 9 | 2025 | 35497 | 0.090 |
Why?
| | Mice, Inbred DBA | 3 | 2007 | 190 | 0.090 |
Why?
| | Asthma | 1 | 2024 | 2229 | 0.090 |
Why?
| | Biopsy | 1 | 2014 | 1092 | 0.090 |
Why?
| | Citrulline | 2 | 2008 | 44 | 0.090 |
Why?
| | Carcinogenesis | 2 | 2022 | 213 | 0.090 |
Why?
| | Rheumatoid Factor | 2 | 2008 | 166 | 0.080 |
Why?
| | Porphyromonas gingivalis | 1 | 2008 | 20 | 0.080 |
Why?
| | Freund's Adjuvant | 1 | 2008 | 19 | 0.070 |
Why?
| | Periodontitis | 1 | 2008 | 49 | 0.070 |
Why?
| | Antibodies, Bacterial | 1 | 2008 | 137 | 0.070 |
Why?
| | HIV Infections | 2 | 2019 | 2721 | 0.070 |
Why?
| | Joints | 1 | 2008 | 101 | 0.070 |
Why?
| | Complement C3 | 1 | 2008 | 208 | 0.070 |
Why?
| | Immunoglobulin Isotypes | 1 | 2006 | 34 | 0.070 |
Why?
| | Lupus Vulgaris | 1 | 2006 | 4 | 0.060 |
Why?
| | Antigen-Antibody Reactions | 1 | 2006 | 52 | 0.060 |
Why?
| | Antibody Specificity | 1 | 2006 | 184 | 0.060 |
Why?
| | Apoptosis | 1 | 2014 | 2499 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2537 | 0.060 |
Why?
| | Immunization | 1 | 2008 | 411 | 0.060 |
Why?
| | Synovial Membrane | 1 | 2006 | 90 | 0.060 |
Why?
| | Cohort Studies | 3 | 2021 | 5409 | 0.060 |
Why?
| | Child | 1 | 2025 | 20785 | 0.060 |
Why?
| | Fibrinogen | 1 | 2006 | 163 | 0.060 |
Why?
| | Paneth Cells | 1 | 2023 | 16 | 0.050 |
Why?
| | Cattle | 1 | 2006 | 977 | 0.050 |
Why?
| | Butyrates | 1 | 2023 | 57 | 0.050 |
Why?
| | Plant Extracts | 1 | 2025 | 198 | 0.050 |
Why?
| | Cholelithiasis | 2 | 1992 | 36 | 0.050 |
Why?
| | Azoxymethane | 1 | 2022 | 19 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5051 | 0.050 |
Why?
| | Dextran Sulfate | 1 | 2022 | 78 | 0.050 |
Why?
| | 4-Nitroquinoline-1-oxide | 1 | 2022 | 8 | 0.050 |
Why?
| | Lactobacillus | 1 | 2022 | 26 | 0.050 |
Why?
| | Quality of Life | 2 | 2025 | 2687 | 0.050 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2022 | 49 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2007 | 815 | 0.050 |
Why?
| | Delayed Diagnosis | 1 | 2021 | 78 | 0.050 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 372 | 0.050 |
Why?
| | Citrullination | 1 | 2020 | 12 | 0.040 |
Why?
| | Interleukin-2 | 1 | 2001 | 437 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2021 | 200 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2022 | 327 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 376 | 0.040 |
Why?
| | Aged | 5 | 2021 | 22032 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 310 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 615 | 0.040 |
Why?
| | Buspirone | 1 | 1998 | 4 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2001 | 427 | 0.040 |
Why?
| | Serotonin Receptor Agonists | 1 | 1998 | 28 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2001 | 772 | 0.040 |
Why?
| | Lorazepam | 1 | 1998 | 26 | 0.040 |
Why?
| | Diet, Western | 1 | 2018 | 79 | 0.040 |
Why?
| | Anti-Anxiety Agents | 1 | 1998 | 45 | 0.040 |
Why?
| | Organ Specificity | 1 | 2018 | 295 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2020 | 505 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2019 | 321 | 0.040 |
Why?
| | Mitochondria | 1 | 2023 | 877 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 6543 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2018 | 233 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 849 | 0.030 |
Why?
| | Bile Acids and Salts | 1 | 2018 | 195 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2019 | 1085 | 0.030 |
Why?
| | Procollagen | 1 | 1976 | 21 | 0.030 |
Why?
| | Qualitative Research | 1 | 2021 | 1215 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2015 | 132 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 1998 | 350 | 0.030 |
Why?
| | Genes, Bacterial | 1 | 2015 | 157 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 481 | 0.030 |
Why?
| | Diet | 1 | 2022 | 1212 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2015 | 361 | 0.030 |
Why?
| | Adiposity | 1 | 2018 | 504 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 380 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2015 | 367 | 0.030 |
Why?
| | Gallbladder Emptying | 1 | 1992 | 1 | 0.030 |
Why?
| | Cell Line | 2 | 2015 | 2779 | 0.030 |
Why?
| | Gallbladder | 1 | 1992 | 17 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2022 | 4887 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 5384 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 730 | 0.020 |
Why?
| | Cholecystectomy | 1 | 1992 | 59 | 0.020 |
Why?
| | Lithotripsy | 1 | 1992 | 43 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2015 | 672 | 0.020 |
Why?
| | Fibroblasts | 1 | 1976 | 948 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1204 | 0.020 |
Why?
| | Liver | 1 | 2018 | 1839 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 1992 | 242 | 0.020 |
Why?
| | Young Adult | 2 | 2019 | 12392 | 0.020 |
Why?
| | Signal Transduction | 2 | 2015 | 4926 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2008 | 160 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2007 | 126 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2008 | 400 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 6391 | 0.020 |
Why?
| | Infant | 1 | 2018 | 8975 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 793 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2007 | 1109 | 0.010 |
Why?
| | Mice, Inbred CBA | 1 | 2001 | 52 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1839 | 0.010 |
Why?
| | Interleukin-12 | 1 | 2001 | 118 | 0.010 |
Why?
| | Peptides | 1 | 2006 | 923 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 20315 | 0.010 |
Why?
| | Manifest Anxiety Scale | 1 | 1998 | 4 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2001 | 1304 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2011 | 0.010 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 1976 | 16 | 0.010 |
Why?
| | Ascorbic Acid | 1 | 1976 | 120 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1998 | 1875 | 0.010 |
Why?
| | Chenodeoxycholic Acid | 1 | 1992 | 14 | 0.010 |
Why?
| | Ursodeoxycholic Acid | 1 | 1992 | 19 | 0.010 |
Why?
| | Food | 1 | 1992 | 156 | 0.010 |
Why?
| | Fasting | 1 | 1992 | 267 | 0.010 |
Why?
| | Odds Ratio | 1 | 1992 | 1019 | 0.010 |
Why?
| | Ultrasonography | 1 | 1992 | 713 | 0.000 |
Why?
| | Incidence | 1 | 1992 | 2636 | 0.000 |
Why?
| | Treatment Outcome | 1 | 1998 | 10202 | 0.000 |
Why?
| | Prospective Studies | 1 | 1992 | 7123 | 0.000 |
Why?
| | Retrospective Studies | 1 | 1992 | 14461 | 0.000 |
Why?
|
|
Kuhn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|